PEC-QT

N/A

Report date: 2025/08/11 17:53:14

Base Information

Drug NamePEC-QT
Drug Alias NameGene-edited stem cell derived allogeneic beta-cell replacement therapyImmune-evasive stem cell therapyPEC-QTVCTX-210
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy
Mechanisms of ActionPancreatic beta cell replacementsProgrammed death-ligand 1 modulatorsBeta-2-microglobulin modulators +[4] 
TargetsProgrammed death-ligand 1Beta-2-microglobulinHLA Class I Histocompatibility Antigen, Alpha Chain E
Therapy Area/IndicationsAutoimmune DiseasesImmune System DiseasesEndocrine System Diseases +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics AgViacyte Inc
China Registration ClassN/A

Develop Information

Active CompaniesViacyte IncCrispr Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesDiabetes Mellitus, Type 1Diabetes Mellitus +[5] 
Inactive IndicationsImmune System DiseasesEndocrine System Diseases

Other Information

ATC CodeN/A
Related LinksN/A